Arcagy Gineco

Recent papers from Arcagy Gineco

1. Pembrolizumab Plus Chemotherapy for Cervical CancerJAMA Oncology · 2026
2. Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMelDermatology and Therapy · 2026
3. Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancerTherapeutic Advances in Medical Oncology · 2026
4. Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trialTranslational Oncology · 2026
5. Final Results From the ATALANTE/ENGOT-ov29 Randomized Phase III Trial of Atezolizumab, Bevacizumab, and Platinum-Based Therapy for Late-Relapsing Recurrent Ovarian CancerJCO oncology advances. · 2026
6. Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancernpj Digital Medicine · 2026
7. Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancernpj Precision Oncology · 2026
8. TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) and trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC).Journal of Clinical Oncology · 2026
9. NoLEEta: No chemotherapy in intermediate-risk HR+ HER2− early breast cancer treated with ribociclib in the adjuvant setting—A non-inferiority phase III trial.Journal of Clinical Oncology · 2026
10. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)JNCI Journal of the National Cancer Institute · 2026
11. Immuno-molecular features associated with exceptional recurrence–free survivorship from Ovarian Cancer in the pre-PARP eranpj Genomic Medicine · 2026
12. Maintenance of PARP Inhibitor Rechallenge Plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP InhibitorClinical Cancer Research · 2026
13. Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO TrialJCO Precision Oncology · 2026
14. ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO TrialClinical Cancer Research · 2026
15. Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trialNature Communications · 2026
16. Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III TrialJournal of Clinical Oncology · 2025
17. Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III TrialJournal of Clinical Oncology · 2025
18. SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancersTherapeutic Advances in Medical Oncology · 2025
19. Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian CancerJCO Oncology Practice · 2025
20. Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian CancerJCO Oncology Practice · 2025